Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Candida antigen extract patch VDMN-21

An dissolvable microarray-based formulation containing an extract of Candida albicans (C. albicans) antigens, with immunomodulatory activity. Upon administration of the C. albicans antigen extract patch VDMN-21 adjacent to the cutaneous human papilloma virus (HPV)-infected wart(s), the C. albicans antigens, upon release from the microarray, stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against the C. albicans antigens and cause a delayed type hypersensitivity response against other local antigens, including antigens within the wart tissue. This leads to the production of Th1 cytokines, and the activation of natural killer (NK) cell- and CTL- mediated killing of HPV-infected cells. This causes clearing of both local and distant warts, and prevents HPV infection and wart formation that results from HPV infection.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:C. albicans antigen extract patch VDMN-21
Candida antigen extract-containing microneedle patch VDMN-21
Code name:VDMN 21
VDMN-21
VDMN21
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search